- ISIN
- US60853G1067
- CUSIP
- 60853G106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 16, 2021
Highlights
- Market Cap
- $155.67M
- Enterprise Value
- $63.96M
- EPS (TTM)
- -CHF 1.92
- Gross Profit (TTM)
- -CHF 2.61M
- EBITDA (TTM)
- -CHF 63.08M
- Year Range
- $3.46 - $5.36
- Target Price
- $13.00
- ROA (TTM)
- -82.45%
- ROE (TTM)
- -105.58%
- Avg. Volume (1M)
- 5K
- Avg. Volume Value (1M)
- $19.56K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MOLN Performance Chart
Molecular Partners AG (MOLN) is down 9.8% since the beginning of the year. At $4 per share, MOLN is trading 26.7% below its 52-week high of $5. Investors who bought $1,000 worth of MOLN shares 5 years ago would now be looking at an investment worth $193.
Loading charts...
Compare this symbol against anything
Returns By Period
Molecular Partners AG (MOLN) has returned -9.83% so far this year and 11.33% over the past 12 months.
Molecular Partners AG
- 1D
- 0.00%
- 1M
- -1.26%
- 6M
- -7.53%
- YTD
- -9.83%
- 1Y
- 11.33%
- 3Y*
- -13.08%
- 5Y*
- -28.06%
- 10Y*
- —
- ALL TIME*
- -27.21%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
MOLN Monthly Returns History
Based on dividend-adjusted daily data since Jun 16, 2021, MOLN's average daily return is -0.01%, while the average monthly return is -0.72%.
Historically, 37% of months were positive and 63% were negative. The best month was Jun 2024 with a return of +100.8%, while the worst month was Apr 2022 at -60.8%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.
On a daily basis, MOLN closed higher 42% of trading days. The best single day was Oct 21, 2024 with a return of +39.2%, while the worst single day was Apr 27, 2022 at -37.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.49% | 18.18% | -20.98% | 6.58% | -0.71% | -7.85% | 1.55% | -9.83% | |||||
| 2025 | 8.68% | -2.52% | -22.86% | 0.51% | -2.24% | 0.20% | -3.14% | 1.35% | -1.07% | -2.06% | 13.43% | 5.75% | -8.20% |
| 2024 | 14.36% | -10.04% | -2.33% | -9.98% | -4.79% | 100.83% | 18.67% | -33.80% | -10.44% | 5.36% | 8.58% | -18.42% | 13.59% |
| 2023 | -1.53% | -3.10% | -3.39% | 9.14% | -2.58% | -3.12% | -3.78% | -0.08% | -30.77% | -14.73% | 18.98% | -0.48% | -36.18% |
| 2022 | 42.60% | -11.70% | -14.91% | -60.83% | -5.59% | -10.79% | -8.70% | -5.33% | 14.16% | -6.87% | 2.73% | 2.34% | -65.85% |
| 2021 | 2.45% | -0.44% | 2.75% | -6.44% | -5.10% | -24.72% | 36.90% | -4.10% |
Benchmark Metrics
Molecular Partners AG has an annualized alpha of -8.21%, beta of 0.50, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 16, 2021.
- This stock participated in 190.56% of S&P 500 Index downside but only 37.40% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.50 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -8.21%
- Beta
- 0.50
- R²
- 0.01
- Upside Capture
- 37.40%
- Downside Capture
- 190.56%
Return for Risk
Risk / Return Rank
MOLN ranks 49 for risk / return — above 49% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Molecular Partners AG (MOLN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MOLN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.31 | ||
| Sortino ratioReturn per unit of downside risk | -1.38 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.25 | -0.18 |
| Calmar ratioReturn relative to maximum drawdown | 0.23 | 2.00 | -1.78 |
| Martin ratioReturn relative to average drawdown | 0.41 | 8.49 | -8.08 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Molecular Partners AG. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Molecular Partners AG was 89.59%, occurring on Apr 19, 2024. The portfolio has not yet recovered.
The current Molecular Partners AG drawdown is 87.68%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-89.59%Apr 2024 | 2y 3mo | — | 4y 6moJan 2022 - now | — |
-52.45%Nov 2021 | 4mo 22d | 1mo 23d | 6mo 15dJun 2021 - Jan 2022 | — |
-3.75%Jun 2021 | 8d | 4d | 12dJun 2021 - Jun 2021 | — |
Drawdown Indicators
| MOLN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.59% | -56.78% | -32.81% |
Max Drawdown (1Y)Largest decline over 1 year | -27.61% | -9.10% | -18.51% |
Max Drawdown (3Y)Largest decline over 3 years | -68.48% | -18.90% | -49.58% |
Max Drawdown (5Y)Largest decline over 5 years | -89.59% | -25.43% | -64.16% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.68% | -1.58% | -86.10% |
Average DrawdownAverage peak-to-trough decline | -72.49% | -10.70% | -61.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.21% | 2.14% | +13.07% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Molecular Partners AG over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Molecular Partners AG is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MOLN in comparison with other companies in the Biotechnology industry. Currently, MOLN has a P/B value of 1.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MOLN
Add Molecular Partners AG to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MOLN